Zacks Research Brokers Increase Earnings Estimates for PAHC

Key Points

• Zacks Research has increased its Q2 2026 earnings per share (EPS) estimate for Phibro Animal Health from $0.60 to $0.71, while maintaining a "Hold" rating on the stock.
• Bank of America raised its price target for Phibro Animal Health from $19.00 to $27.00 and issued an "underperform" rating, illustrating mixed analyst views on the stock.
• The company recently announced a quarterly dividend of $0.12 per share, representing an annual yield of 1.2%, with a payout ratio of 40.68%.

Phibro Animal Health Corporation (NASDAQ:PAHC - Free Report) - Equities research analysts at Zacks Research upped their Q2 2026 earnings per share (EPS) estimates for shares of Phibro Animal Health in a report issued on Wednesday, September 10th. Zacks Research analyst Team now forecasts that the company will earn $0.71 per share for the quarter, up from their prior forecast of $0.60. Zacks Research has a "Hold" rating on the stock. The consensus estimate for Phibro Animal Health's current full-year earnings is $1.95 per share. Zacks Research also issued estimates for Phibro Animal Health's Q3 2026 earnings at $0.66 EPS, Q1 2027 earnings at $0.58 EPS, Q2 2027 earnings at $0.69 EPS, Q3 2027 earnings at $0.62 EPS, Q4 2027 earnings at $0.59 EPS, FY2027 earnings at $2.49 EPS and FY2028 earnings at $2.92 EPS.

A number of other equities analysts have also recently weighed in on the stock. Bank of America upped their price objective on shares of Phibro Animal Health from $19.00 to $27.00 and gave the company an "underperform" rating in a research report on Friday, August 29th. Morgan Stanley set a $34.00 price objective on Phibro Animal Health in a report on Thursday, August 28th. BNP Paribas Exane upgraded Phibro Animal Health from an "underperform" rating to a "neutral" rating and set a $24.00 price objective on the stock in a report on Monday, June 16th. BNP Paribas upgraded Phibro Animal Health to a "hold" rating in a report on Monday, June 16th. Finally, JPMorgan Chase & Co. upgraded Phibro Animal Health from a "neutral" rating to an "overweight" rating and lifted their price objective for the stock from $25.00 to $35.00 in a report on Monday, July 7th. One equities research analyst has rated the stock with a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of "Reduce" and a consensus target price of $28.40.

Phibro Animal Health Stock Performance

NASDAQ:PAHC opened at $41.18 on Thursday. The company has a debt-to-equity ratio of 2.46, a current ratio of 2.76 and a quick ratio of 1.25. The firm has a 50-day moving average of $31.49 and a two-hundred day moving average of $25.25. The stock has a market cap of $1.67 billion, a P/E ratio of 34.90, a PEG ratio of 1.23 and a beta of 0.89. Phibro Animal Health has a 1-year low of $16.16 and a 1-year high of $41.57.

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) last issued its quarterly earnings data on Wednesday, August 27th. The company reported $0.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.52 by $0.05. Phibro Animal Health had a net margin of 3.73% and a return on equity of 32.14%. The company had revenue of $378.70 million during the quarter, compared to the consensus estimate of $362.24 million. Phibro Animal Health has set its FY 2026 guidance at 2.520-2.700 EPS.

Phibro Animal Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 24th. Investors of record on Wednesday, September 3rd will be given a dividend of $0.12 per share. The ex-dividend date is Wednesday, September 3rd. This represents a $0.48 dividend on an annualized basis and a yield of 1.2%. Phibro Animal Health's payout ratio is currently 40.68%.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PAHC. Nuveen LLC acquired a new position in Phibro Animal Health during the 1st quarter valued at approximately $10,312,000. Invesco Ltd. boosted its position in Phibro Animal Health by 92.3% during the 1st quarter. Invesco Ltd. now owns 387,739 shares of the company's stock valued at $8,282,000 after purchasing an additional 186,087 shares during the period. Ranger Investment Management L.P. boosted its position in Phibro Animal Health by 101.1% during the 2nd quarter. Ranger Investment Management L.P. now owns 357,970 shares of the company's stock valued at $9,143,000 after purchasing an additional 179,975 shares during the period. Axecap Investments LLC bought a new stake in Phibro Animal Health during the 1st quarter valued at $3,696,000. Finally, Millennium Management LLC raised its stake in Phibro Animal Health by 74.3% during the 1st quarter. Millennium Management LLC now owns 362,030 shares of the company's stock valued at $7,733,000 after acquiring an additional 154,281 shares in the last quarter. Institutional investors and hedge funds own 99.34% of the company's stock.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.